Discover Great Companies Discover Great Clients
Companies Salaries Jobs
Jobs |
Jobs Companies Salary Majors

Company Overview

Development Stage

  • Stage: B+轮,数亿人民币。

About the Company

鑫康合生物医药成立于2015年11月,公司基于世界前沿的科研成果,以精准创新为导向,致力于肿瘤和自身免疫性炎症疾病全新靶点或者创新性组合的药物开发,创新性免疫治疗抗体药物研发。
依托全球知名的科学顾问委员会和深耕抗体药物领域十余年的海归研发核心团队,公司已建成高水平的创新型抗体研发核心技术平台,包括高效的抗体制备平台,精准的筛选平台以及先进的体内外药效和转化医学平台。
秉承“创新、精准、优质、专注”的研发理念,通过自主研发及资源合作等方式,在全力研制针对肿瘤及自身免疫性疾病单抗一类新药的同时,全力打造植根于中国并具全球视野的抗体新药研发公司。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

鑫康合 Financing History (2 rounds)

Manage
B+轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 数亿人民币
  • Investor: 高瓴创投,阳光保险,顺禧基...

鑫康合 Related Industry Tags

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 1,465.739万(元)
Legal Representative: 王亚宁
Date Established:
Credit Code: 91320594MA1MB78N70
Registered Address: 浙江省绍兴市柯桥区安昌街道柯海大道1299号东盛慧谷7幢8楼801室

People who follow 鑫康合 also follow

鑫康合 Competitors (Similar Companies)

“致力于分子靶向药物和免疫肿瘤药物研发,及商业创新领域”
“专注于抗体药物的创新型生物医药企业”
“医药行业龙头企业之一”
医药 原料药 制药/药业 生产
医药 生物医药 单克隆抗体药物 高通量筛选
医药 制药 原料药 制药/药业
“把数字世界带入每个人、每个家庭、每个组织,构建万物互联的智能世界。”
医药 生物医药 CRO 再生医学
“创新只为生命”
“恶性肿瘤、自身免疫疾病、眼科等重大疾病的新药研发创制”
药物研发 抗肿瘤药 肿瘤治疗 研发
材料科技
医药 生物医药 医疗科技 医药科技
“派格生物医药拥有一条从高分子聚乙二醇合成到聚乙二醇药物修饰的上下游贯通的产业链。”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates

户外娱乐
客服
由百度提供